Brazil plans to update the regulatory framework, expand production of medical products

15 August 2014
brazil-big

The Brazilian Ministry of Health has opened a public consultation to establish the criteria for product development partnerships (PDPs) for the health sector, writes Juliane Carvalho on Brazil Pharma News.

The proposal seeks to consolidate a new regulatory framework adopted by the federal government for the management of partnership agreements between the public and private institutions seeking to produce medicines, medical equipment and strategic materials for Brazil's Unified Health System (SUS). Among the main advantages is the strengthening of federal government management and the determination of deadlines for companies to submit their proposals for technology transfers. The proposed regulation will be available for public comments until August 28.

"We are consolidating this policy into a single legislative instrument and strengthening the security and governance of the entire product development partnerships process. The Ordinance sets up a state policy in which decisions are made between the ministries,” said Health Minister Arthur Chioro.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical